VivoSeq
Cardiovascular

Cardiac Arrest

71

Pipeline Programs↗

17

Active Trials↗

29

Companies Involved↗

Cardiac Arrest is a moderately active landscape with 71 programs across 29 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Pfizer, Hope Pharmaceuticals. 14 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

66/100

Pipeline Velocity

22/100

Mech. Concentration

9/100

Completion Rate

85/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 1Pfizer logo

Pfizer

4 programs

Phase 2H

Hope Pharmaceuticals

1 program

Phase 2S

Scienture

1 program

Phase 2P

Pascoe Pharmazeutische Praeparate GmbH

1 program

Phase 2R

Resolve Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical10

Atropine

Fresenius Kabi Oncology Ltd.

Cisatracurium

AbbVie

Venous Lactate

Centre Hospitalier Universitaire de Nice

Antiplatelet Drug

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Serum NGAL Level

Yonsei University

Phase 13

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Nitrite

Orthopedic Foot and Ankle Center, Ohio

Packed Red Blood Cells

NYU Langone Health

Phase 222

Tocilizumab

Roche

Sodium Nitrite

Hope Pharmaceuticals

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

Aminophylline

The Searle Company Limited Pakistan

Potassium Chloride

Novartis

Phase 322

Dexamethasone

Aspen Global Incorporated

Vasopressin

Aultman Health Foundation

Amiodarone

Wyeth-Lederle Vaccines

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Olanzapine

MODAG GmbH

Approved14

Ticagrelor

AstraZeneca

Cangrelor

Chiesi Farmaceutici S.p.A.

Ketamine

Aultman Health Foundation

Sodium Bicarbonate

Abbott

Cyclosporine

Novartis

Analysis

Modality Breakdown

98%

Small molecule

83 of 85 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody11%Protein / enzyme11%

Small molecule leads; the ring shows all 85 classified programs, each share of the total. Modality classified for 100% of 90 pipeline programs.

Analysis

Trial Status

90

clinical trials

Completed50 · 56%
Unknown status14 · 16%
Recruiting12 · 13%
Terminated5 · 6%
Withdrawn4 · 4%
Not yet recruiting3 · 3%
Other2 · 2%

Clinical Trials

Trial Activity

90 trials

The Danish Out-of-Hospital Cardiac Arrest Study
Recruiting·—·Phase 3·NCT05895838·1,000 enrolled
Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients
Recruiting·—·Phase 4·NCT06572085·350 enrolled
Packed Red Blood Cell Transfusion During Cardiac Arrest
Recruiting·NNYU Langone Health·Phase 1·NCT06462027·30 enrolled
Hypertonic Lactate After Cardiac Arrest
Recruiting·EErasme University Hospital·Phase 2·NCT05004610·125 enrolled
Prophylactic Anti-aRrhythmic Therapy With Amiodarone in Critically Ill Patients Admitted for an Out-of-hospital Cardiac Arrest With Initial Shockable Rhythm
Recruiting·VVersailles Hospital·Phase 3·NCT06835491·674 enrolled
VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical Trial
Recruiting·TTiohundra AB·Phase 3·NCT05139849·1,276 enrolled
Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.
Recruiting·—·Phase 2·NCT05817851·234 enrolled
Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest
Recruiting·—·Phase 2·NCT06744361·282 enrolled
Early Amiodarone in Shockable Cardiac Arrest
Recruiting·OOregon Health and Science University·Phase 3·NCT06680869·585 enrolled
Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)
Recruiting·—·Phase 4·NCT06353334·100 enrolled
Study of the Occurrence of Cardiocirculatory Arrest as a Function of the Level of Hypoxemia During a Maastricht 3 Procedure. Prospective Observational Multicenter Study
Recruiting·NNantes University Hospital·N/A·NCT06780722·50 enrolled
The fMRI in CardiaC arrEst With Uncertain Prognosis (FACE-UP) Study
Recruiting·BBrigham and Women's Hospital·N/A·NCT06423768·50 enrolled
Bicarbonate for In-Hospital Cardiac Arrest
Active, not recruiting·—·Phase 4·NCT05564130·778 enrolled
The CPR, Pre-hospital ECPR and Early Reperfusion Study: A Target Trial Emulation (CHEER4TTE)
Active, not recruiting·AAustralian and New Zealand Intensive Care Research Centre·N/A·NCT07679737·250 enrolled
Epinephrine Versus Isoprenaline During Out-of-Hospital Cardiac Arrest With Asystole
Not yet recruiting·UUniversity of Southern Denmark·Phase 4·NCT06473116·1,178 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)